{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=25",
    "query": {
      "condition": "Recombinant",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 1029,
    "total_pages": 103,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recombinant&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T01:10:35.534Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01468896",
      "title": "Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Unresectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Edodekin alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2011-10-26",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Columbus, Ohio",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01468896"
    },
    {
      "nct_id": "NCT00423046",
      "title": "Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Papillomavirus",
        "Papillomavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gardasil ® (Merck & Co. Inc)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 1106,
      "start_date": "2007-01-24",
      "completion_date": "2012-05-14",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 40,
      "location_summary": "Chandler, Arizona • San Diego, California • San Francisco, California + 36 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "West Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423046"
    },
    {
      "nct_id": "NCT07227246",
      "title": "Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intracerebral Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIIa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biological/Vaccine: Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Joseph Broderick, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 350,
      "start_date": "2025-05-06",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fontana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227246"
    },
    {
      "nct_id": "NCT00300950",
      "title": "Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlobeImmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2006-01",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-04-06",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00300950"
    },
    {
      "nct_id": "NCT01977482",
      "title": "Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaemia"
      ],
      "interventions": [
        {
          "name": "GSK1278863",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "rhEPO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 216,
      "start_date": "2013-11-01",
      "completion_date": "2015-02-06",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 17,
      "location_summary": "Azusa, California • Los Angeles, California • San Dimas, California + 13 more",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "West Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01977482"
    },
    {
      "nct_id": "NCT00989196",
      "title": "Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Human-cl rhFVIII",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Kogenate FS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2010-05",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sacramento, California • Denver, Colorado + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00989196"
    },
    {
      "nct_id": "NCT00392925",
      "title": "A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "pramlintide acetate 360 mcg",
          "type": "DRUG"
        },
        {
          "name": "metreleptin",
          "type": "DRUG"
        },
        {
          "name": "placebo-pramlintide 600 uL",
          "type": "DRUG"
        },
        {
          "name": "placebo-metreleptin 1 mL",
          "type": "DRUG"
        },
        {
          "name": "Pramlintide acetate 180 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 177,
      "start_date": "2006-10",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-14",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 12,
      "location_summary": "DeLand, Florida • Chicago, Illinois • Indianapolis, Indiana + 9 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00392925"
    },
    {
      "nct_id": "NCT01100528",
      "title": "Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ciliary Body and Choroid Melanoma, Medium/Large Size",
        "Ciliary Body and Choroid Melanoma, Small Size",
        "Iris Melanoma",
        "Recurrent Intraocular Melanoma"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 38,
      "start_date": "2009-11-11",
      "completion_date": "2017-12-14",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01100528"
    },
    {
      "nct_id": "NCT01547728",
      "title": "Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thrombophilia Due to Acquired Antithrombin III Deficiency"
      ],
      "interventions": [
        {
          "name": "Recombinant antithrombin (rhAT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 42,
      "start_date": "2012-02",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2015-07-15",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01547728"
    },
    {
      "nct_id": "NCT00772265",
      "title": "Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Wosulin N",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Novolin N",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Wockhardt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 56,
      "start_date": "2010-09",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2012-12-27",
      "last_synced_at": "2026-10-27T01:10:35.534Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00772265"
    }
  ]
}